Toronto, Ontario--(Newsfile Corp. - April 14, 2026) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) (&#34;Cardiol&#34; or the &#34;Company&#34;), a late-stage life sciences company focused on advancing the development of

<p>Toronto, Ontario--(Newsfile Corp. - April 14, 2026) - Cardiol Therapeutics Inc. <b>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/CRDL">CRDL</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/quote/CRDL">CRDL</a>) </b>("<b>Cardiol</b>" or the "<b>Company</b>"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that Cardiol's President and Chief Executive Officer, David Elsley, will participate in a live interview on <b>X</b> with <a href="https://api.newsfilecorp.com/redirect/24Z11T1wzA">Barchart.com</a> ("Barchart") today at 12:00 p.m. EDT.</p><p><b>Interview Topics:</b></p><ul style="list-style-type: disc;"><li>The ongoing pivotal Phase III MAVERIC trial of CardiolRx&#8482; in recurrent pericarditis</li><li>Results from the recently published Phase II ARCHER trial of CardiolRx&#8482; in acute myocarditis</li><li>The Company's next generation drug, CRD-38, in development for heart failure</li></ul><p><b>Interview details:</b></p><p><b>Date:</b> April 14, 2026<br /><b>Time:</b> 12:00 PM EDT<br /><b>Platform:</b> <b>X</b><br /><b>Host Account on X:</b> @Barchart<br /><b>Join Live Interview at: </b><a href="https://api.newsfilecorp.com/redirect/Mq5MMsq2vm">x.com/Barchart</a></p><p>After the event, a full recording of the interview will be available on the Company's <b>X </b>channel (@CardiolRx) and Barchart's (@Barchart).</p><p><b>About Cardiol Therapeutics</b></p><p>Cardiol Therapeutics Inc. <b>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/CRDL">CRDL</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/quote/CRDL">CRDL</a>)</b> is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company's lead small-molecule drug candidate, CardiolRx&#8482;, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.</p><p>The MAVERIC Program is evaluating CardiolRx&#8482; for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations. The program comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing pivotal Phase III MAVERIC trial (NCT06708299). The U.S. FDA has granted Orphan Drug Designation to CardiolRx&#8482; for the treatment of pericarditis, including recurrent pericarditis.</p><p>The ARCHER Program is also studying CardiolRx&#8482;, specifically in acute myocarditis&#8212;an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in individuals under 35 years of age. The program comprises the completed Phase II ARCHER study (NCT05180240), which evaluated the safety, tolerability, and efficacy of CardiolRx&#8482; in this patient population.</p><p>The Company is also developing CRD-38, a novel, subcutaneously administered drug formulation intended for the treatment of inflammatory heart disease, including heart failure&#8212;a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding US$30 billion per year.</p><p>For more information about Cardiol Therapeutics, please visit <a href="https://api.newsfilecorp.com/redirect/bgKwwI1kgG">cardiolrx.com</a>.</p><p><b>Cautionary statement regarding forward-looking information:</b><br /><i>This news release contains "forward-looking information" within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are "forward-looking information". Forward-looking information contained herein may include, but is not limited to statements regarding the Company's focus on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease; the Company's intended clinical studies and trial activities and timelines associated with such activities, including the Company's plan to complete the Phase III study in recurrent pericarditis with CardiolRx&#8482;; the Company's plan to advance the development of CRD-38, a novel subcutaneous formulation intended for the treatment of inflammatory heart disease, including heart failure. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company's Annual Information Form filed with the Canadian securities administrators and U.S. Securities and Exchange Commission on March 31, 2026, available on SEDAR+ at <a href="https://api.newsfilecorp.com/redirect/3KZEEseg4w">sedarplus.ca</a> and EDGAR at <a href="https://api.newsfilecorp.com/redirect/N3LmmfPMxb">sec.gov</a>, as well as the risks and uncertainties associated with product commercialization and clinical studies. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information, and such information may not be appropriate for other purposes. Any forward-looking information speaks only as of the date of this press release and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events, or results, or otherwise. Investors are cautioned not to rely on these forward-looking statements.</i></p><div id="contactInfo"><p>For further information, please contact:<br /><a href="mailto:Investor.relations@cardiolrx.com">Investor.relations@cardiolrx.com</a></p></div><p id="corporateNewsLogoContainer"><img src="https://images.newsfilecorp.com/files/5704/292336_9b1f2755d457e9ca_logo.jpg" id="corporateNewsLogo" alt="Corporate Logo" /></p><p id="corporateLinkBack">To view the source version of this press release, please visit <a href="https://api.newsfilecorp.com/redirect/XEKqqtM0aQ">https://www.newsfilecorp.com/release/292336</a></p><p><img src="https://api.newsfilecorp.com/newsinfo/292336/197" alt="" /></p>

CRDL

Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart

Cardiol Therapeutics CEO Discusses Key Heart Disease Trials in Live Interview

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>Toronto, Ontario--(Newsfile Corp. - April 14, 2026) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) (&amp;#34;Cardiol&amp;#34; or the &amp;#34;Company&amp;#34;), a late-stage life sciences company focused on advancing the development of</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Cardiol Therapeutics&#039; CEO will participate in a live interview focusing on the pivotal MAVERIC Phase III trial of CardiolRx, the promising results from the ARCHER Phase II study, and the development of their new drug, CRD-38, for heart failure. This could enhance CRDL&#039;s market position as investors seek updates on these critical advancements.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>CRDL CEO to discuss CardiolRx in live interview today.</li><li>Ongoing Phase III MAVERIC trial is a key focus.</li><li>Results from Phase II ARCHER trial show potential efficacy.</li><li>CRD-38, a new drug for heart failure, is in development.</li><li>FDA granted Orphan Drug Designation for CardiolRx treatment.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Barchart.com</strong>: Hosting the live interview; could enhance visibility for CRDL.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This fits into &#039;Corporate Developments&#039; as the live interview provides critical updates on ongoing trials and new drug development, which directly influences CRDL&#039;s business prospects and potential revenue streams.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Positive trial results could significantly boost CRDL&#039;s share price.</li><li>Increased investor interest following high-profile interview could drive volume.</li><li>Regulatory developments may enhance valuation of CardiolRx and CRD-38.</li><li>Successful trial outcomes may attract partnerships or acquisitions.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>MAVERIC trial (NCT06708299) is pivotal for recurrent pericarditis treatment.</li><li>ARCHER trial (NCT05180240) results have shown promising safety and efficacy.</li><li>CRD-38 is targeted for inflammatory heart disease and heart failure.</li><li>U.S. FDA has granted Orphan Drug Designation to CardiolRx.</li><li>Interview is scheduled for today at 12 PM EDT.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>CRDL is a buy in the near term due to potential positive trial outcomes.</p>
  </section>
</section>


<p>Toronto, Ontario--(Newsfile Corp. - April 14, 2026) - Cardiol Therapeutics Inc. <b>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/CRDL">CRDL</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/quote/CRDL">CRDL</a>) </b>("<b>Cardiol</b>" or the "<b>Company</b>"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that Cardiol's President and Chief Executive Officer, David Elsley, will participate in a live interview on <b>X</b> with <a href="https://api.newsfilecorp.com/redirect/24Z11T1wzA">Barchart.com</a> ("Barchart") today at 12:00 p.m. EDT.</p><p><b>Interview Topics:</b></p><ul style="list-style-type: disc;"><li>The ongoing pivotal Phase III MAVERIC trial of CardiolRx&#8482; in recurrent pericarditis</li><li>Results from the recently published Phase II ARCHER trial of CardiolRx&#8482; in acute myocarditis</li><li>The Company's next generation drug, CRD-38, in development for heart failure</li></ul><p><b>Interview details:</b></p><p><b>Date:</b> April 14, 2026<br /><b>Time:</b> 12:00 PM EDT<br /><b>Platform:</b> <b>X</b><br /><b>Host Account on X:</b> @Barchart<br /><b>Join Live Interview at: </b><a href="https://api.newsfilecorp.com/redirect/Mq5MMsq2vm">x.com/Barchart</a></p><p>After the event, a full recording of the interview will be available on the Company's <b>X </b>channel (@CardiolRx) and Barchart's (@Barchart).</p><p><b>About Cardiol Therapeutics</b></p><p>Cardiol Therapeutics Inc. <b>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/CRDL">CRDL</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/quote/CRDL">CRDL</a>)</b> is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company's lead small-molecule drug candidate, CardiolRx&#8482;, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.</p><p>The MAVERIC Program is evaluating CardiolRx&#8482; for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations. The program comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing pivotal Phase III MAVERIC trial (NCT06708299). The U.S. FDA has granted Orphan Drug Designation to CardiolRx&#8482; for the treatment of pericarditis, including recurrent pericarditis.</p><p>The ARCHER Program is also studying CardiolRx&#8482;, specifically in acute myocarditis&#8212;an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in individuals under 35 years of age. The program comprises the completed Phase II ARCHER study (NCT05180240), which evaluated the safety, tolerability, and efficacy of CardiolRx&#8482; in this patient population.</p><p>The Company is also developing CRD-38, a novel, subcutaneously administered drug formulation intended for the treatment of inflammatory heart disease, including heart failure&#8212;a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding US$30 billion per year.</p><p>For more information about Cardiol Therapeutics, please visit <a href="https://api.newsfilecorp.com/redirect/bgKwwI1kgG">cardiolrx.com</a>.</p><p><b>Cautionary statement regarding forward-looking information:</b><br /><i>This news release contains "forward-looking information" within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are "forward-looking information". Forward-looking information contained herein may include, but is not limited to statements regarding the Company's focus on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease; the Company's intended clinical studies and trial activities and timelines associated with such activities, including the Company's plan to complete the Phase III study in recurrent pericarditis with CardiolRx&#8482;; the Company's plan to advance the development of CRD-38, a novel subcutaneous formulation intended for the treatment of inflammatory heart disease, including heart failure. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company's Annual Information Form filed with the Canadian securities administrators and U.S. Securities and Exchange Commission on March 31, 2026, available on SEDAR+ at <a href="https://api.newsfilecorp.com/redirect/3KZEEseg4w">sedarplus.ca</a> and EDGAR at <a href="https://api.newsfilecorp.com/redirect/N3LmmfPMxb">sec.gov</a>, as well as the risks and uncertainties associated with product commercialization and clinical studies. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information, and such information may not be appropriate for other purposes. Any forward-looking information speaks only as of the date of this press release and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events, or results, or otherwise. Investors are cautioned not to rely on these forward-looking statements.</i></p><div id="contactInfo"><p>For further information, please contact:<br /><a href="mailto:Investor.relations@cardiolrx.com">Investor.relations@cardiolrx.com</a></p></div><p id="corporateNewsLogoContainer"><img src="https://images.newsfilecorp.com/files/5704/292336_9b1f2755d457e9ca_logo.jpg" id="corporateNewsLogo" alt="Corporate Logo" /></p><p id="corporateLinkBack">To view the source version of this press release, please visit <a href="https://api.newsfilecorp.com/redirect/XEKqqtM0aQ">https://www.newsfilecorp.com/release/292336</a></p><p><img src="https://api.newsfilecorp.com/newsinfo/292336/197" alt="" /></p>

Cardiol Therapeutics' CEO will participate in a live interview focusing on the pivotal MAVERIC Phase III trial of CardiolRx, the promising results from the ARCHER Phase II study, and the development of their new drug, CRD-38, for heart failure. This could enhance CRDL's market position as investors seek updates on these critical advancements.

Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News